High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 5, 2014, Pages 646-653

  Feng, Yan ^a,b   Minca, Eugen C ^b   Lanigan, Christopher ^b   Liu, Angen ^b   Zhang, Wei ^a   Yin, Lihong ^a   Pennell, Nathan A ^a,b   Farver, Carol ^a   Tubbs, Raymond ^b   Ma, Patrick C ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

ALK Gene rearrangement; Crizotinib; HGF; MET; Non small cell lung cancer

Indexed keywords

CRIZOTINIB; SCATTER FACTOR RECEPTOR; ANAPLASTIC LYMPHOMA KINASE; MET PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SCATTER FACTOR;

ADULT; ALK GENE; ARTICLE; CHROMOSOME 2P; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MET GENE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; CHROMOSOME 2; GENETICS; LUNG NEOPLASMS; SIGNAL TRANSDUCTION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOMES, HUMAN, PAIR 2; FEMALE; GENE AMPLIFICATION; GENE REARRANGEMENT; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION;

EID: 84899115483     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000145     Document Type: Article

References (29)

1. Feng Y Thiagarajan PS Ma PC. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 2012;7:459-467.
2. Beau-Faller M Ruppert AM Voegeli AC et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol 2008;3:331-339.
3. Olivero M Rizzo M Madeddu R et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996;74:1862-1868.
4. Engelman JA Zejnullahu K Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043.
5. Cappuzzo F Jänne PA Skokan M et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009;20:298-304.
6. Bean J Brennan C Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-20937.
7. Sequist LV Waltman BA Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
8. Scagliotti G Novello S Ramlau R et al. MARQUEE: A randomized double-blind placebo-controlled phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC). European Cancer Congress 2013. Abstract E17-1821.
9. Ou SH Kwak EL Siwak-Tapp C et al. Activity of crizotinib (PF02341066) a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942-946.
10. Soda M Choi YL Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
11. Kwak EL Bang YJ Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
12. Gainor JF Varghese AM Ou SH et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013;19:4273-4281.
13. Wong DW Leung EL So KK et al.; University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-1733.
14. Cui JJ Tran-Dubé M Shen H et al. Structure based drug design of crizotinib (PF-02341066) a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011;54:6342-6363.
15. Minca EC Portier BP Wang Z et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 2013;15:341-346.
16. Lee HE Kim MA Lee HS et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 2012;107:325-333.
17. Yan B Lim M Zhou L et al. Identification of MET genomic amplification protein expression and alternative splice isoforms in neuroblastomas. J Clin Pathol 2013;66:985-991.
18. Santoro A Rimassa L Borbath I et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised placebo-controlled phase 2 study. Lancet Oncol 2013;14:55-63.
19. Dziadziuszko R Wynes MW Singh S et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 2012;7:340-347.
20. Shaw AT Yeap BY Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
21. Tsuta K Kozu Y Mimae T et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol 2012;7:331-339.
22. Ma PC Tretiakova MS MacKinnon AC et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008;47:1025-1037.
23. Onitsuka T Uramoto H Ono K et al. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor K-ras MET and hepatocyte growth factor status. J Thorac Oncol 2010;5:591-596.
24. Onozato R Kosaka T Kuwano H Sekido Y Yatabe Y Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009;4:5-11.
25. Cappuzzo F Marchetti A Skokan M et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-1674.
26. Kanteti R Yala S Ferguson MK Salgia R. MET HGF EGFR and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol 2009;28:89-98.
27. Kondo S Ojima H Tsuda H et al. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol 2013;18:207-213.
28. Gunia S Erbersdobler A Hakenberg OW Koch S May M. C-MET is expressed in the majority of penile squamous cell carcinomas and correlates with polysomy-7 but is not associated with MET oncogene amplification pertinent histopathologic parameters or with cancer-specific survival. Pathol Res Pract 2013;209:215-220.
29. Kosa C Kardos L Kovacs J Szollosi Z. Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment. Pathol Res Pract 2013;209:147-150.